Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc. reported a substantial year-over-year growth in Cell Processing revenue, which increased by 33% to $25.3 million, contributing to total revenues of $28.1 million for Q3 2025, reflecting a 31% growth on a proforma basis. The company achieved a net income of $0.6 million, or $0.01 per share, surpassing previous loss estimates, alongside projected gross margins in the low-60% range for 2025 and continued improvements in adjusted EBITDA margins. Additionally, BioLife's strategic initiatives, including the establishment of a Center to enhance biopreservation and cell processing best practices, are anticipated to further drive the adoption of its products and services within the cell and gene therapy sector.

Bears say

BioLife Solutions Inc. faces significant risks that contribute to a negative outlook, including potential lower-than-projected growth of its products and services, challenges in securing additional customers, and fluctuations in sales driven by emerging markets and foreign exchange rates. Additionally, the company's FY2025 revenue guidance was adjusted downward by approximately $8 million, resulting in an expected revenue range of $95.0-96.0 million, which reflects a moderate year-over-year growth of 27-29%. This adjustment further emphasizes the reliance on its primary revenue driver, the Cell Processing platform, which is forecasted to generate $93.0-94.0 million but also highlights risks associated with concentrated revenue sources.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.